No correlation between RET immunostaining and the codon 918 mutation in sporadic medullary thyroid carcinoma
Standard
No correlation between RET immunostaining and the codon 918 mutation in sporadic medullary thyroid carcinoma. / Bockhorn, M; Frilling, A; Kalinin, V; Schröder, S; Broelsch, C E.
in: LANGENBECK ARCH SURG, Jahrgang 384, Nr. 1, 01.02.1999, S. 60-4.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - No correlation between RET immunostaining and the codon 918 mutation in sporadic medullary thyroid carcinoma
AU - Bockhorn, M
AU - Frilling, A
AU - Kalinin, V
AU - Schröder, S
AU - Broelsch, C E
PY - 1999/2/1
Y1 - 1999/2/1
N2 - INTRODUCTION: Medullary thyroid carcinoma (MTC) occurs sporadically or as part of the inherited cancer syndrome, multiple endocrine neoplasia (MEN) type 2. The MEN2 gene has been identified as the RET proto-oncogene. Mutations in the RET proto-oncogene are associated with the pathogenesis of MTC. Approximately 23-40% of sporadic MTCs (sMTCs) have a somatic RET codon 918 mutation within the catalytic core of the tyrosine kinase, which is a mutation found in over 98% of all MEN 2B cases as a germline mutation.METHODS: In order to elucidate the role of this mutation, we examined 40 sMTCs for the codon 918 mutation. Simultaneously, we looked for overexpression of the RET protein by means of immunohistochemistry with a newly developed RET antibody.RESULTS: In 8 of 40 tumors (20%), we were able to find a RET codon 918 mutation. Nine of 40 tumors (22.5%) showed immunoreactivity with the RET antibody.CONCLUSION: The presence of the somatic RET codon 918 mutations did not correlate with the presence of positive RET immunostaining.
AB - INTRODUCTION: Medullary thyroid carcinoma (MTC) occurs sporadically or as part of the inherited cancer syndrome, multiple endocrine neoplasia (MEN) type 2. The MEN2 gene has been identified as the RET proto-oncogene. Mutations in the RET proto-oncogene are associated with the pathogenesis of MTC. Approximately 23-40% of sporadic MTCs (sMTCs) have a somatic RET codon 918 mutation within the catalytic core of the tyrosine kinase, which is a mutation found in over 98% of all MEN 2B cases as a germline mutation.METHODS: In order to elucidate the role of this mutation, we examined 40 sMTCs for the codon 918 mutation. Simultaneously, we looked for overexpression of the RET protein by means of immunohistochemistry with a newly developed RET antibody.RESULTS: In 8 of 40 tumors (20%), we were able to find a RET codon 918 mutation. Nine of 40 tumors (22.5%) showed immunoreactivity with the RET antibody.CONCLUSION: The presence of the somatic RET codon 918 mutations did not correlate with the presence of positive RET immunostaining.
KW - Carcinoma, Medullary
KW - Codon
KW - Humans
KW - Immunohistochemistry
KW - Multiple Endocrine Neoplasia Type 2a
KW - Mutation
KW - Protein-Tyrosine Kinases
KW - Proto-Oncogene Proteins
KW - Proto-Oncogenes
KW - Thyroid Neoplasms
M3 - SCORING: Journal article
C2 - 10367632
VL - 384
SP - 60
EP - 64
JO - LANGENBECK ARCH SURG
JF - LANGENBECK ARCH SURG
SN - 1435-2443
IS - 1
ER -